[{"address1": "Maxim 1", "address2": "2 Parklands Way Holytown", "city": "Motherwell", "zip": "ML1 4WR", "country": "United Kingdom", "phone": "44 14 1433 7557", "website": "https://tcbiopharm.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.", "fullTimeEmployees": 41, "companyOfficers": [{"maxAge": 1, "name": "Mr. Bryan L. Kobel", "age": 44, "title": "CEO & Director", "yearBorn": 1979, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Martin E. Thorp", "age": 71, "title": "CFO & Director", "yearBorn": 1952, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher  Camarra", "title": "Executive Vice President of Communications", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lauren  Bor Ph.D.", "title": "Head of Commercial Development Division", "exercisedValue": 0, "unexercisedValue": 0}], "maxAge": 86400, "priceHint": 4, "previousClose": 1.61, "open": 1.52, "dayLow": 1.3, "dayHigh": 1.54, "regularMarketPreviousClose": 1.61, "regularMarketOpen": 1.52, "regularMarketDayLow": 1.3, "regularMarketDayHigh": 1.54, "beta": 0.328, "forwardPE": -0.2847826, "volume": 367288, "regularMarketVolume": 367288, "averageVolume": 4732329, "averageVolume10days": 9155200, "averageDailyVolume10Day": 9155200, "bid": 1.28, "ask": 1.33, "bidSize": 200, "askSize": 400, "marketCap": 4185620, "fiftyTwoWeekLow": 0.85, "fiftyTwoWeekHigh": 380.0, "fiftyDayAverage": 1.36558, "twoHundredDayAverage": 47.211704, "currency": "USD", "enterpriseValue": 83051008, "floatShares": 63766527, "sharesOutstanding": 3195130, "sharesShort": 204482, "sharesShortPriorMonth": 196991, "sharesShortPreviousMonthDate": 1709164800, "dateShortInterest": 1711584000, "sharesPercentSharesOut": 0.084300004, "heldPercentInsiders": 0.00034000003, "heldPercentInstitutions": 0.02407, "shortRatio": 0.03, "shortPercentOfFloat": 0.084300004, "bookValue": 2.611, "priceToBook": 0.50172347, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -5906953, "trailingEps": -23.93, "forwardEps": -4.6, "enterpriseToEbitda": -6.103, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "TCBP", "underlyingSymbol": "TCBP", "shortName": "TC BioPharm (Holdings) plc", "longName": "TC Biopharm (Holdings) Plc", "firstTradeDateEpochUtc": 1644589800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ef544858-646b-3e8d-bcb0-2aed3539a593", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.31, "targetHighPrice": 140.0, "targetLowPrice": 140.0, "targetMeanPrice": 140.0, "targetMedianPrice": 140.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 2462609, "totalCashPerShare": 0.039, "ebitda": -13609267, "totalDebt": 1801157, "quickRatio": 0.749, "currentRatio": 1.2, "debtToEquity": 67.076, "returnOnAssets": -0.88012004, "returnOnEquity": -3.91644, "freeCashflow": -12229230, "operatingCashflow": -10544870, "financialCurrency": "GBP", "trailingPegRatio": null, "__fetch_time": "2024-04-16"}]